| Description: |
A simple blood test can detect early markers of "reinvigorated" T cells and track immune responses in metastatic melanoma patients after initial treatment with the anti-PD-1 drug pembrolizumab, researchers report. The new findings give more insight into how the new anti-PD-1 therapy, approved last year by the U.S. Food and Drug Administration to treat metastatic melanoma, goes to work inside patients' bodies, and potentially form the basis of a biomarker to predict which patients are most apt to respond to the immunotherapy. [Source: University of Pennsylvania]
|
 |
